Search

Displaying results 5311 - 5320 of 10000 in total
  1. Drug

    VTX-801

    go.drugbank.com/drugs/DB17646
    Investigational

    It is being investigated in Wilson Disease.[L45924] … VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the

  2. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation … Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.

  3. Drug

    Methyl salicylate 2-ethylbutyrate

    go.drugbank.com/drugs/DB14130
    Investigational

    Mixtures: Thera Derm Roll On
  4. Drug

    Fenthion

    go.drugbank.com/drugs/DB11412
    ExperimentalVet approved

    Fenthion is an _organothiophosphate_ drug used as an insecticide, avicide, and acaricide. … Fenthion is listed as a restricted use compound by the United States Environmental Protection Agency due to its potential to cause cholinesterase inhibition in humans and animals.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  6. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  7. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    It is currently in phase I trials.

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … mutations in the kinase domain of FGFR.

  9. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  10. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]